AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06745596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery 1
Description: Cataract with limited anterior pars plana vitrectomy
Study NCT06745596 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cataract surgery 2
Description: cataract without limited anterior pars plana vitrectomy
Study NCT06744699 — intervention group
Intervention type: OTHER
Intervention: Infants fed goat milk-based infant formula
Description: Type of infant feeding during the age of 0-12 months
Study NCT06743919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 50% - 1g/h
Description: magnesium sulfate group 20 ml bupivacaine 0.25% plus 500 mg magnesium sulfate in 5ml normal saline on both sides.
Study NCT06743919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine 0.5 µg/kg IV
Description: dexmedetomidine group 20 ml bupivacaine 0.25% plus o .5 microg per kg dexmedetomidine in 5 ml normal saline on both sides.
Study NCT06743919 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: 20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
Study NCT06743919 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 20 ml bupivacaine 0.25% plus 5 ml normal saline on both sides.
Study NCT06745219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: herombopag
Description: receive harombopag for the prevention of thrombocytopenia in the next cycle of chemotherapy
Study NCT06200116 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT06743763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: fNIRS-based neurofeedback
Description: fNIRS-based neurofeedback is provided during a simulated classroom scenario where the child participants are asked to learn to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
Study NCT06743763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: fNIRS-based neurofeedback
Description: fNIRS-based neurofeedback is provided during a simulated classroom scenario where the child participants are asked to learn to regulate their attention based on the feedback provided by the fNIRS on the oxygenated haemoglobin level in their prefrontal cortex.
Study NCT04928287 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HB-adMSCs
Description: HB-adMSCs will be administered intravenously to study participants who qualify.
Study NCT04928287 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: HB-adMSCs
Description: HB-adMSCs will be administered intravenously to study participants who qualify.
Study NCT06743763 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Simulated Classroom
Description: A simulated classroom scenario is integrated in VR setting and children are asked to complete academic tasks in the simulated classroom.
Study NCT06743763 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Reality Simulated Classroom
Description: A simulated classroom scenario is integrated in VR setting and children are asked to complete academic tasks in the simulated classroom.
Study NCT06744660 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Aptitude Medical Systems Metrix COVID Test
Description: The Metrix COVID Test is a real-time reverse transcription loop-mediated isothermal amplification reaction (RT-LAMP) test that has been designed to detect viral RNA from SARS-CoV-2 via electrochemical detection using the Metrix Reader. Detection of SARS-CoV-2 gene targets will produce a positive SARS-CoV-2 result. If no target is detected and the internal control amplifies, the result is negative. If no amplification is detected in any of the channels, an invalid result is displayed.
Study NCT06744374 — intervention group
Intervention type: DRUG
Intervention: BGF
Description: Budesonide/glycopyrrolate/formoterol fumarate
Study NCT06744374 — intervention group
Intervention type: DRUG
Intervention: MITT
Description: Multiple-inhaler triple therapy
Study NCT04744662 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham injection
Description: sham injection is done by touching the eye surface with a syringe without a needle
Study NCT06745687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM336
Description: Patients received subcutaneous CM-336 80 mg once weekly in 28-d cycles after two step-up priming doses of 3 mg and 20 mg given on day 1 and day 4 of cycle 1 and cycle2. Then patients will be given 160mg every 2 weeks from cycle 3 to cycle 6. The dosing interval is adjusted according to the evaluation of efficacy every 6 cycles from cycle 7 to cycle 24.
Study NCT06745089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intense pulsed light
Description: Intense pulsed light exerts photothermal, photochemical effects, and photobiomodulation on meibomian glands.
Study NCT06745089 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: thermal pulsation therapy
Description: Thermal pulsation therapy utilizes local heating and massage on the eyelids.
Study NCT06745089 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ocular lubricant
Description: Ocular lubricants moisturize the ocular surface.
Study NCT04928287 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously to study participants who qualify.
Study NCT04928287 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered intravenously to study participants who qualify.
Study NCT06745791 — intervention group
Intervention type: DEVICE
Intervention: BoneMRI
Description: BoneMRI is a quantitative 3D MRI technique,capable of generating CT-like, quantitative radiodensity bone MRI images to visualize cortical and trabecular bone, allowing to assess bone structure and morphology, in addition to regular clinical MRI images.
Study NCT04938349 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual task perturbation training
Description: Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
Study NCT04938349 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dual task perturbation training
Description: Participants will play six cognitive games targeting working memory, executive functioning, visuomotor reactions, and language fluency provided in standing. Following which they will receive 12 slips without performing cognitive task (Single task training) at the highest intensity and 12 slips during standing while performing a cognitive task (dual task). Also, they will then undergo 12 dual task walking trials (at self-selected speed) followed by 12 walking slips.
Study NCT06183164 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness: Awareness-Based Stress Reduction Program
Description: The mindfulness-based stress reduction program was applied to the patients in the experimental group once a week, for 150 minutes, for 8 weeks and 8 times in total. Then, an intermediate test is applied to the patients. After the interim test, patients are asked to repeat the mindfulness-based stress reduction program individually for 8 weeks (between weeks 8-16). In addition, after the conscious awareness-based stress reduction program is applied to the patients in the experimental group by the researcher, the 'Conscious Awareness-Based Stress Reduction Program' booklet prepared by the researcher is given to the patients as a guide. experimental group.
Study NCT04758403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Navigation Bronchoscopy
Description: Navigation Bronchoscopy procedure will be performed per product instructions and the institution's standard practice.
Study NCT04758403 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Cone beam computed tomography (CBCT)
Description: Per Protocol
Study NCT05811208 — intervention group
Intervention type: DEVICE
Intervention: automated pupillometry
Description: Automated pupillometry every 6 hours
Study NCT05811208 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaire
Description: CAM ICU questionnaire will be used for delirium screening the incidence of pain will be assessed using 3 valid scales. The Visual Analogue Scale (VAS), the Behavioral Pain Scale (BPS) and the Critical Care Observational Tool (CPOT) will be used.~questionnaires will be done the same time as pupillometry
Study NCT04634877 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV infusion
Study NCT05940649 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Continuous norepinephrine administration
Description: In patients randomized to continuous norepinephrine administration, hypotension (= mean arterial pressure \< 65mmHg) will be treated with continuous norepinephrine infusion. The norepinephrine perfusion line will be connected to the saline infusion line using a three-way valve. Treating anesthesiologists will be free to reduce or increase the norepinephrine infusion rate anytime.
Study NCT05394051 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Affect Regulation sKills (PARK)
Description: The goal of the PARK program is to reduce feelings of anxiety, depression, and social isolation, as well as increase well-being and a sense of meaning and purpose through the practice of positive emotion skills via a self-guided online platform.~The total time involved from the beginning to the end of the intervention portion of the study is approximately 6 months (includes 6-week PARK course, baseline and follow-up assessments. Wait list controls will be assessed at similar time intervals and will be offered PARK at end of follow-up.
Study NCT06290037 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VR Driving Simulator
Description: Evaluation of usual road driving abilities and assessment of response capabilities in accident-prone situations through a VR driving simulator
Study NCT06290037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Computerized Neurocognitive Function Test
Description: Evaluation of cognitive levels including attention and memory (the Trail Making Test, Digit Span Test, Auditory (or Visual) Continuous Performance Test , and Card Sorting)
Study NCT06290037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Driver Test Station
Description: Conducting qualified tests of a person's basic physical driving ability including steering, acceleration and braking, using Driver Test Station(Autoadapt AB, Stenkullen, Sweden)
Study NCT06290037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Short Physical Performance Battery
Description: Evaluation of functional capability and provide a measure of the biological age of an older individual by measuring lower extremity physical performance status(standing balance, walking speed, and chair stand tests).
Study NCT06290037 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: On-road field driving Test
Description: Researchers and driver's license supervisors ride in the driver's license test vehicle to evaluate the subject's actual driving ability. the validity of the VR simulator by comparing the results of the VR simulator with the actual vehicle driving ability.
Study NCT06518642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma tDCS portable device - active stimulation
Description: Treatment followed common tDCS protocol upon considering safety and tolerability, comprising five consecutive sessions in five days of 30-minute 2 mA tDCS. We utilized the Soterix Medical tDCS device (Soterix Medical, New York, NY, USA, Model 1x1 tDCS-CT) in the research lab and the Sooma Oy device (Sooma Depression Therapy Comfort, Helsinki, Finland) for patient self-administration.Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device.Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or. Due to the limited availability of the Sooma devices, participants were randomly allocated to either the Sooma or the Soterix device based on availability during their initial session. A current of 2 mA was applied with the anode positioned left DLPFC, corresponding to area F3 in the international 10-20 system. The cathode (reference electrode) was applied at the right dPLFC, F4.
Study NCT05930535 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting for Lifelong Health for Parents and Teens
Description: PLH will be delivered over 6 sessions as a group-based family program with both adolescents and caregivers attending, with joint and separate core sessions framed by joint introductions and endings. It will include activities such as: building positive parent-child relationships; developing problem-solving skills; stress-management and stress-reduction skills; improving effective limit-setting and discipline by parents; talking about feelings and regulating emotions.~The PLH program will also include a peer support component and incentive boosters. The Helping Adolescents Thrive comic chapters will be provided as homework activities. The comics, developed by UNICEF, cover adaptation to new situations, stress management, problem-solving, communication skills, risky choices and being there for each other.
Study NCT04964752 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: continuous glucose-monitoring
Description: Continuous glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients with diabetes.
Study NCT06518642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sooma tDCS portable device - sham stimulation
Description: Sooma provided two of their portable tDCS devices for a brief period, including one customized sham device for effective blinding, distinguishable only by serial number and managed by an external data manager following the randomization sequence.To ensure blinding to the participant and their caregiver, at the beginning of the stimulation sessions, participants receiving both the active and sham stimulation would experience a ramp-up in current from 0 to 2 mA, and then the current would ramp down to 0 mA for participants receiving sham stimulation. Participants were told that they may experience sensations such as tingling, headache, or mild burning during the first 30-60 seconds of the stimulation session but that they may subside afterwards as they got used to it. In other words, participants would not be able to tell if diminishing of side effects were due to habituation (active tDCS) or ramping down of current (sham tDCS).
Study NCT05706129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-DPI-4452
Description: \[68Ga\]Ga-DPI-4452, administered as IV injection.
Study NCT05706129 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [177Lu]Lu-DPI-4452
Description: \[177Lu\]Lu-DPI-4452, administered as IV infusion.
Study NCT06531512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xianglei Tangzu Gao
Description: Active ingredients: Extracts of Plectranthus amboinicus and Centella Asiatica
Study NCT06531512 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Cream base of Xianglei Tangzu Gao
Study NCT06287606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0302-A
Description: Subjects randomized into group CTP0302-A will take a bowel preparation from the evening until the following morning.
Study NCT06287606 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0302-B
Description: Subjects randomized into group CTP0302-B will take a bowel preparation on the Colonoscopy day
Study NCT06287606 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Conventional OST
Description: Subjects randomized into group Conventional OST will take a bowel preparation from the evening until the following morning.
Study NCT06458426 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: shock-absorbing prosthesis
Description: the intervention will test the difference between rigid and shock-absorbing pylons, while the same prosthetic foot is applied in each condition.
Study NCT04885530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: Each participant will receive a sufficient quantity of 7-mg tablets to be taken as directed based on their weight. The tablets are white, round, biconvex tablets with 123 over the scoring on one side. All packaging will be labeled to indicate that the product is for investigational use.
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: IV infusion
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV infusion
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: IV infusion
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for pembrolizumab
Description: IV infusion
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Docetaxel
Description: IV infusion docetaxel 75 mg/m\^2 Q3W or 25 mg/m2 QW may be given in place of paclitaxel following sponsor consultation if a participant experiences severe hypersensitivity to paclitaxel or an adverse event requiring discontinuation of paclitaxel.
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 75 mg/m\^2 IV infusion Q3W may be given in place of carboplatin following sponsor consultation if a participant experiences severe hypersensitivity to carboplatin or an adverse event requiring discontinuation of carboplatin.
Study NCT04634877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External Beam Radiotherapy (EBRT)
Description: ≥4500 cGY given according to local practice, at the discretion of the investigator
Study NCT04634877 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: External Beam Radiotherapy (EBRT)
Description: ≥4500 cGY given according to local practice, at the discretion of the investigator
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (as radiosensitizer)
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Study NCT04634877 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin (as radiosensitizer)
Description: If a participant receives external beam radiotherapy (EBRT), then cisplatin 50 mg/m\^2 IV infusion may be administered as a radiosensitizer at the discretion of the investigator, on days 1 and 29
Study NCT04634877 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Brachytherapy
Description: Given according to local practice, at the discretion of the investigator
Study NCT04634877 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Brachytherapy
Description: Given according to local practice, at the discretion of the investigator
Study NCT05064280 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pembrolizumab
Description: Given by IV (200 mg IV D1 Q3W)
Study NCT05064280 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenvatinib
Description: Given by PO (20 mg PO QD)
Study NCT04936490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crocin
Description: 15 mg/d
Study NCT04885530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluvoxamine
Description: Fluvoxamine is a round golden 50 mg tablet that is scored on both sides - one side has APO and the other side has F50 with a partial bisect. All packaging will be labeled to indicate that the product is for investigational use, administered at a dose of 50 mg, twice daily for 10 days.
Study NCT04885530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone
Description: Fluticasone furoate is an inhaled powder drug product composed of fluticasone furoate. It is a synthetic trifluorinated corticosteroid that is insoluble in water. Fluticasone furoate is a white powder and will be provided in a two tone grey inhaler with a mouthpiece cover and separate foil blister strips. The inhaler will be packaged in a moisture-protective foil tray with a desiccant and a peelable lid.All packaging will be labeled to indicate that the product is for investigational use. Participants will self-administer 200 µg (1 blister) of fluticasone furoate once daily for 14 days.
Study NCT04936490 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 15 mg/d
Study NCT06148259 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: International prostate symptom score
Description: Questionnaire of 8 questions to be administered to all patients about prostate symptoms